Glauconix Biosciences Inc, a specialty pharmaceutical company, announced yesterday that it has named Kimberly Southern as its new chief operating officer.
Southern has more than 20 years of experience in building and leading companies in various industries, most recently as COO at New England Peptide in Gardner, Massachusetts.
In her new role, she will steer the company's business strategies, drive operational execution, and further develop the company's R&D initiatives and intellectual property portfolio.
Glauconix is located on the SUNY Polytechnic Institute Campus in Albany, which is affiliated with the Center for Advanced Technology in Nanomaterials and Nanoelectronics (CATN2).
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business